[gdpawel]

Don't see why Afinitor can't be used off-label for BC. There are a number of new classes of drugs that target VEGF, at the protein level (Avastin), at the tyrosine kinase level (Nexavar, Sutent) and at the intracellular metabolic pathway mTOR (Afinitor, Torisel). Responses to any individual mechanism occurs in the miniority (subset) of patients. It is unclear why some patients respond to these interventions while others fail. This reinforces the need for cancer therapies to be individualized. It remines us that it is the good outcome of the patient not the therapy applied that constitute successful therapy.